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httpTissue-engineered blood vessel substitute by
reconstruction of endothelium using mesenchymal
stem cells induced by platelet growth factors
Matheus Bertanha, MSc,a,b Andrei Moroz, PhD,b,c Rodrigo Almeida, BSc,b Flavia Cilene Alves, PhD,b
Michele Janegitz Acorci Valério, PhD,b Regina Moura, PhD,a Maria Aparecida Custódio Domingues, PhD,d
Marcone Lima Sobreira, PhD,a and Elenice Deffune, PhD,b,e Botucatu, Brazil
Background: Cardiovascular diseases remain leaders as the major causes of mortality in Western society. Restoration of the
circulation through construction of bypass surgical treatment is regarded as the gold standard treatment of peripheral
vascular diseases, and grafts are necessary for this purpose. The great saphenous vein is often not available and synthetic
grafts have their limitations. Therefore, new techniques to produce alternative grafts have been developed and, in this
sense, tissue engineering is a promising alternative to provide biocompatible grafts. This study objective was to recon-
struct the endothelium layer of decellularized vein scaffolds, using mesenchymal stem cells (MSCs) and growth factors
obtained from platelets.
Methods: Fifteen nonpregnant female adult rabbits were used for all experiments. Adipose tissue and vena cava were ob-
tained and subjected to MSCs isolation and tissue decellularization, respectively. MSCs were subjected to differentiation
using endothelial inductor growth factor (EIGF) obtained from human platelet lysates. Immunoﬂuorescence, histological
and immunohistochemical analyses were employed for the ﬁnal characterization of the obtained blood vessel substitute.
Results: The scaffolds were successfully decellularized with sodium dodecyl sulfate. MSCs actively adhered at the scaffolds,
and through stimulation with EIGF were differentiated into functional endothelial cells, secreting signiﬁcantly higher
quantities of von Willebrand factor (0.85 mg/mL; P < .05) than cells cultivated under the same conditions, without EIGF
(0.085 mg/mL). Cells with evident morphologic characteristics of endothelium were seen at the lumen of the scaffolds.
These cells also stained positive for fascin protein, which is highly expressed by differentiated endothelial cells.
Conclusions: Taken together, the use of decellularized bioscaffold and subcutaneous MSCs seems to be a potential
approach to obtain bioengineered blood vessels, in the presence of EIGF supplementation. (J Vasc Surg 2014;59:1677-85.)
Clinical Relevance: The reported outcomes and techniques on this paper may be employed to constitute decellularized
heterologous blood vessel banks. These specimens may be seeded with the patients’ own mesenchymal stem cells, which
can be differentiated into functional endothelial cells that secrete von Willebrand factor. This is done through a novel
approach using a concentrate of growth factors obtained from the patient’s own platelets, also described in this article.
Extra steps would be the seeding of smooth muscle cells and adventitial ﬁbroblasts, which also could be differentiated
from the patient’s mesenchymal stem cells. Finally, an autologous blood vessel substitute can be obtained for cardio-
vascular peripheral disease graft treatment. These grafts will not induce tissue rejection, as the donor cells are completely
removed and replaced by the patient’s cells.Recent reports have aimed to provide better alternative
biocompatible options for vascular conduits such as human
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://dx.doi.org/10.1016/j.jvs.2013.05.032thelial cells in polymers.1-3 Tissue engineering has provided
a new kind of conduit using different techniques,4-6 often
employing three-dimensional (3D) scaffolds followed by
cell seeding.7,8 These can be differentiated cells previously
expanded in vitro, or mesenchymal stem cells (MSCs),9 fol-
lowed by the differentiation to the desired cell.10,11 By
using MSCs, one can rapidly obtain high cell counting,
faster than differentiated cells are able to.12 Moreover,
several tissues may be used as the harvesting site. Among
them, adipose tissue is a preferred choice due to the high
concentration of MSCs present at the stromal-vascular frac-
tion in this tissue (which can be collected in a low invasive
procedure that offers equal differentiation capabilities of
other tissue sources).13,14
To obtain a functional endothelium from MSCs, these
cells require direct stimulation with growth factors that
induce endothelial differentiation.15 Given that the two
principal growth factors that modulate this differentiation,
the platelet-derived growth factor16,17 and vascular1677
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let’s granules,19-21 in physiological concentrations, we
developed a novel way to differentiate MSCs into endothe-
lial cells.
Researchers have inferred that it is possible to deploy
cells at synthetic scaffolds such as biodegradable polymers1
or organic tissues that were previously decellularized,
obtaining in vitro tissue specimens.22-24 It is, therefore,
possible to yield cardiovascular conduits, with equivalent
quality such as in the native artery, thus lowering the risk
of tissue rejection and improving patency rates. Moreover,
the production of organs employing heterologous decellu-
larized scaffolds is already under preclinical and clinical
trials25 and have demonstrated lower rejection rates.26
This study reports the production of a blood vessel
substitute through tissue engineering, using a 3D bio-
scaffold from a decellularized rabbit vena cava, followed
by the reconstruction of the endothelium, with adipose
tissue-derived MSCs and platelet-derived growth factors.
METHODS
Animal housing conditions and general plan of
investigation. Fifteen nonpregnant female adult rabbits
(New Zealand) were used for all experiments. All proce-
dures were conducted respecting the Ethic Guidelines for
Animal Experimentation, after the approval by the Brazil-
ian College for Animal Experimentation (COBEAeProcess
n 711). The rabbits were housed in controlled conditions
and fed a standard pellet diet and water ad libitum. Median
age was 6 months and weight between 2 and 3 kg.
In ﬁve rabbits, subcutaneous adipose tissue was excised
and MSCs harvested. The cava veins were removed from
all rabbits and decellularized. MSCs were then incubated
with the decellularized scaffolds and subjected to endothelial
cell stimulation using endothelial inductor growth factor
(EIGF), which were obtained from human platelet-lysates.
Cell adhesion and endothelial differentiation were assessed
by general histology, immunoﬂuorescence, immunohisto-
chemistry, and von Willebrand factor (vWF) secretion, as
described in the following sections.
Adipose tissue and cava vein harvesting. The animals
were anesthetized with an intramuscular injection of
20 mg/kg of tiletamine hydrochloride/zolazepam hydro-
chloride and 4 mg/kg of 2% xylazine chloridate. The areas
of tissue harvesting were previously shaved and disinfected
with water-soluble iodine polyvinyl pyrrolidone solution.
All following procedures were conducted under aseptic
conditions.
Adipose tissue samples were surgically removed from
interscapular region, from ﬁve animal donors. The infrarenal
inferior vena cava was removed from each animal and the
animals were euthanized using high doses of pentobarbital.
Adipose tissue was immediately stored in a sterile cell culture
medium (RPMI1640; Invitrogen, Carlsbad, Calif) supple-
mented with 100 U/mL penicillin, 100 mg/mL strepto-
mycin, and 25 mg/mL amphotericin B (Invitrogen). The
vena cava and vessel lumens were washed off with sterile
saline solution, supplemented with unfractionated heparin(1000 UI/100 mL). All tissue samples were stored in the
refrigerator at 4C for 24 hours prior to conducting the
experiments.
Adipose-derived MSC expansion. Adipose tissue-
derived MSCs were obtained as previously described,27
through digestion reaction with type I collagenase (Invit-
rogen). Cell culture procedures started with 2  104 cells/
cm2 seeding and expansion in six-well culture plates
(Techno Plastic Products, Trasadingen, Switzerland) with
Dulbecco’s modiﬁed Eagle’s medium nutrient F12 mixture
medium, supplemented with 10% fetal bovine serum (FBS),
100 U/mL penicillin, 100 mg/mL streptomycin, 25 mg/
mL amphotericin B (2 mmol/L L-glutamine; Invitrogen),
1% (v/v) minimum essential medium (MEM) essential
amino acids solution (50; Invitrogen), and 0.5% (v/v) of
10 mM MEM nonessential amino acids solution (100;
Invitrogen) until reaching 80% conﬂuence, when the ob-
tained monolayers were detached from culture wells with
0.25% trypsin/ethylenediaminetetraacetic acid (Invitrogen)
and seeded at 75 cm2 culture ﬂasks (Nunc, Roskilde,
Denmark). After two more trypsin exposures (passages),
cells were cryopreserved with ice-cold FBS supplemented
with 10% dimethyl sulfoxide and stored at a liquid nitrogen
cylinder.
MSC characterization. MSC characterization was
conducted as previously described.28 Brieﬂy, following the
third cell culture passage, cells were characterized using
speciﬁc antibodies designed for ﬂow cytometry. Anti-CD90
antibody (clone OX-7, cross-reactivity with rabbit; Bio-
legend) was used as a positive marker for MSCs. Anti-CD34
and anti-CD45 antibodies (Biolegend, San Diego, Calif)
were employed as negative markers. Anti-mouse-IgG
conjugated with ﬂuorescein isothiocyanate was used as the
secondary antibody (Molecular Probes, Eugene, Ore).
Further analysis was conducted with the FacsCalibur (BD
Biosciences, San Jose, Calif) equipment and software to
obtain the number of positive CD90 cells. Additionally, the
obtained MSCs were investigated for their potential
to differentiate into the osteogenic, chondrogenic, and adi-
pogenic lineages, under the recommended differentiation
cell culture media (StemPro adipogenesis, chondrogenesis,
and osteogenesis kits; Invitrogen) (data not shown).
Scaffold decellularization. Scaffolds were decellular-
ized as described,29 inside a sterile 1% sodium dodecyl
sulfate (SDS) solution, over a period of 2 hours. The
remaining SDS was removed through repetitive washing
with Dulbecco’s phosphate-buffered saline (Invitrogen).
Cell-to-scaffold adhesion characterization. To verify
the feasibility of the decellularized scaffolds, a cell adhesion
test was performed. One vial of cryopreserved characterized
MSCs (from one animal donor) was thawed with viability
accessed by Trypan Blue staining. Cells were labeled as
described,30 with modiﬁcations, with the Qtracker 605
Cell Labeling Kits (Molecular Probes) respecting the
manufacturer’s instructions. Brieﬂy, 1  106 cells were
mixed in 200 mL of culture medium/1.5 mL of prepared
Qtracker solution (Life Technologies, Carlsbad, Calif) and
incubated at 37C for 60 minutes. The labeled cells were
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hydrogel (BD Biosciences), and applied at the lumens of
the decellularized vein scaffolds, with repetitive pipetting
(20 mL/pipetting), until all the solution was applied. This
mixture of PuraMatrix/cells (BD Biosciences) was allowed
to polymerize inside the lumen of the decellularized blood
vessels. The experiment was conducted in triplicate. These
cell-labeled-seeded scaffolds were further incubated for
30 minutes at a 37C 5% CO2 incubator with culture
medium. These were then fast-frozen in liquid nitrogen
for histology/immunoﬂuorescence assessment. Scaffold
sections were obtained at the cryostat (Leica, Wetzlar,
Germany) and analyzed at a ﬂuorescencemicroscope (BX41;
Olympus, Shinjuku, Tokyo, Japan).
Production of EIGFs. The differentiation inductors
were obtained from eight human platelet concentrate units
from the excess stock of the Botucatu Blood Transfusion
Unit that were going to be discarded. The growth factors
that are present inside platelets are encoded by highly
conserved DNA sequences amongst human and rabbit
species, and human growth factors have already proven to
induce response in rabbit cells.31 These units were not
submitted to frozen-thawing cycles. The mean platelet
counts were obtained by automatic counting hardware (LH
750; Beckman Coulter, Brea, Calif) and the platelets were
centrifuged at 5000 rpm for concentration. Supernatant was
discarded and the platelet pellet was washed two times with
sterile D-PBS. Platelet pellets obtained from the eight units
were pooled together, dissolved at sterile injection water
(10 mL) and shaken for 5 minutes (500 rpm) to obtain the
platelet lysates. After a second centrifugation, the superna-
tant was collected to obtain the ﬁnal EIGF.
Endothelial differentiation cell culture. Character-
ized MSCs from four animal donors were seeded at the
2 cm heterologous decellularized vein fragments at 1 
105 cells/fragment and submitted to endothelial differenti-
ation composed of M199 culture medium supplemented
with 20% of EIGF (vol/vol), 100 U/mL penicillin, 100
mg/mL streptomycin, 25 mg/mL amphotericin B (Invi-
trogen), 2 mmol/L L-glutamine (Invitrogen), 1% (v/v)
MEM essential amino acids solution (50; Invitrogen),
and 0.5% (v/v) of 10 mM MEM nonessential amino acids
solution (100; Invitrogen). Cells were pippeted at the
luminal portion of the vein fragments and cultivated at
24-well ultra-low attachment culture plates (Corning;
Sigma-Aldrich, St. Louis, Mo) to minimize cell attachment
to the culture plate, while maximizing attachment to the
scaffolds. Additional experiments were performed as
follows: control, composed of scaffolds and M199 culture
medium; and culture medium control, composed of scaf-
folds, MSCs, and regular M199 medium, without endo-
thelial inductors. Eight vein fragments were employed for
each experiment. All experiments were conducted in
duplicate.
Endothelial cell culture differentiation was performed
for 3 weeks, with culture medium being exchanged every
48 hours. At the end of the experiments, fragments were
collected for histology and immunohistochemical analysis.Cell culture was performed in a stress-free environment
with no mechanical forces applied.
Quantiﬁcation of vWF on conditioned medium.
After the third week of endothelial differentiation protocol,
the conditioned medium (CM) of the different cell cultures
were collected for the quantiﬁcation of vWF, using the
respective enzyme-linked immunosorbent assay (Corgenix,
Inc, Broomﬁeld, Colo), according to manufacturer’s
guidelines. Fresh culture medium and fresh culture
medium supplemented with 20% of EIGF (vol/vol) were
also loaded as controls. Human normal serum was loaded
as positive controls. The integrated optical density was
accessed at a 450 nm capable spectrophotometer reader,
and the obtained values were divided by the values ob-
tained with positive controls. Data was analyzed with
INSTAT software (GraphPad Software, San Diego, Calif)
using the one-tail Student t-test (P < .05) to compare
the different treatments. The respective concentrations
were extrapolated from standards (positive control) and are
represented in mg/mL. Values were calculated as mean 6
standard deviation of the totality of concentrations for the
CM of cells cultivated under regular medium and with
EIGF supplementation (seven independent samples of
each, and the remaining one was employed during the
standardization of the technique).
Histologic and immunohistochemical analysis.
After 3 weeks, cell-seeded scaffolds were prepared for
histological evaluation as described.28 The histologic anal-
ysis was conducted, aiming to conﬁrm the presence of cells
adhered to the internal side of the scaffolds, such as observed
at the immunoﬂuorescence analysis. All eight fragments of
the scaffolds were screened at the microscope (at 200
magniﬁcation), and the images were digitalized. Extra slides
were prepared for immunohistochemical analysis conducted
as previously described.32 These used the anti-fascin
monoclonal antibody (clone 55K-2; Dako, Glostrup,
Denmark), previously described as a high expressed protein
in endothelial cells.33,34 Additionally, the decellularized
scaffolds were processed for general morphology assessment
with Masson’s trichrome staining to conﬁrm the success of
cell removal. Native veins were also processed as normal
controls.
RESULTS
Adipose-derived MSC expansion and characteriza-
tion. After 2 days of the initial seeding of the cells, two
different cell populations could be observed at the inverted
microscope: nonadherent cells in suspension and adherent
cells on the bottom of the culture ﬂasks. The cells in
suspension, typically white blood cells derived from the
stromal-vascular portion of the processed adipose tissue,
were ﬂushed away during the culture medium exchanges.
The adherent cells remained attached to the ﬂasks (Fig 1,
A) and started to proliferate. After the following 2 days,
these cells started to assemble into colonies (Fig 1, B) and
presented classical morphologic characteristics of MSCs:
ﬁbroblastic-shaped, small cell body, deﬁned nucleus, pres-
ence of cytoplasmic projections, and presence of two
Fig 1. Mesenchymal stem cells (MSCs) morphology observed at phase-contrast inverted microscopy and character-
ization by ﬂow cytometry. A, Initial cell adhesion to the culture ﬂasks (arrows), low conﬂuence. MSCs features
ﬁbroblastic-like morphology, well-deﬁned nucleus, and two nucleoli (scale bar ¼ 50 mm). B, Cells proliferated and
colonies are obtained, featuring the same morphologic characteristics (scale bar ¼ 100 mm). C, After the third passage,
cells are cultivated until 100% conﬂuence for CD90 cell characterization (scale bar ¼ 200 mm). D, CD90 positive cells,
recognized as MSCs, constitute all cells in the gated area (M1) of the ﬂow cytometry analysis.
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systematically observed during the entire cultivation period
and still could be seen at the third passage (Fig 1, C). At
this point, the cells were characterized as MSCs by CD90
expression, with values ranging from 95% to 98% and
median of 96.5% (Fig 1, D). The negative markers CD34
and CD45 had expected results, with positive counts
ranging from 0.05% to 1.32% (data not shown). Negative
control (MSCs  secondary antibody) resulted in 0.04%
positive counts (data not shown). The obtained cells
differentiated into osteogenic, chondrogenic, and adipo-
genic cells, using the respective StemPro differentiation
kits, further characterizing them as MSCs (data not
shown).
Scaffold decellularization. Native veins processed as
controls displayed regular morphology with intact endo-
thelium and presence of many nuclei at the subjacent tissue
(Fig 2, A). The SDS decellularization protocol was
successfully employed, and all cells were removed from the
tissue. No nuclei were left either at the endothelium,
smooth muscle layer, and the perivascular connective tissue
(Fig 2, B). The extracellular matrix (ECM) was slightly
disorganized due to SDS exposure; however, large collagen
content was preserved and stained in blue, at the Masson’s
trichrome staining (Fig 2, B). A total of 30 decellularized
vein fragments (2 cm) were obtained.
Cell-to-scaffold adhesion characterization. It was
possible to observe that the scaffolds were able to sustaincell adherence at all samples processed (Fig 3, A-D).
Although the cells were concentrated at the lumen wall
(Fig 3, A), some cells migrated through the scaffolds to the
inner collagenous matrix (Fig 3, B and D). Some areas in
which the cells remained inside the PuraMatrix (BD
Biosciences) applied to the vessel lumen could also be
observed (Fig 3, C).
Production of EIGFs. The mean platelet count of the
concentrate units was 1.88  1011. The ﬁnal growth factor
concentrate was colorless and did not induce any coagula-
tion when supplemented in the culture medium, as seen
previously in our laboratory (data not published).
Endothelial differentiation cell culture. During the
microscopic examination of the cell cultures, under the
inverted microscope, it was possible to observe cells
adhered to the vessel wall (Fig 4). These cells were
morphologically rounded (Fig 4, A and B), a typical
characteristic of initial cell adhesion. Within 2 weeks, the
adhered cells proliferated, could be seen at the borders of
the scaffolds, and cell morphology became ﬁbroblastic-
shaped (Fig 4, C and D), which is a preliminary charac-
teristic of endothelial cells.
Histologic, immunohistochemical analysis, and
vWF dosage. After the thirdweek of differentiation culture,
cell-seeded scaffolds were processed for general histology.
The lined cells observed at the phase contrast inverted
microscopy and immunoﬂuorescence were conﬁrmed at the
histologic sections and were well organized and with
Fig 2. Native and sodium dodecyl sulfate (SDS)-decellularized vein fragments after histologic processing and Masson’s
trichrome staining. A, Naturally occurring vein morphology with lumen (*), well preserved endothelial cells (arrows),
smooth muscle cells, and multiple nuclei at the inner collagenous tissue (arrowheads) (scale bar ¼ 120 mm). B, Decel-
lularized vein morphology displaying its lumen (*), cell-free endothelium (arrows), and cell-free inner collagenous tissue
(crosses). Note that the thick red layer on A, comprised by endothelial cells and smooth muscle cells, is totally absent on
the decellularized vein fragment. All cells (rejection inductor) were successfully removed (scale bar ¼ 120 mm).
Fig 3. Immunoﬂuorescence analysis of the bioscaffold seeded with mesenchymal stem cells (MSCs) after 60 minutes of
initial seeding. MSCs were stained with Qtracker 605 Cell Labeling Kits (Molecular Probes; Life Technologies) and
diluted at the PuraMatrix peptide hydrogel (BD Biosciences). The stained cells/PuraMatrix solution was applied at the
lumens of the decellularized vein scaffolds, with repetitive pipetting. A, Note the accumulation of cells lined in the
vessel lumen wall (arrow) (scale bar ¼ 300 mm). B, Again, cells lined on the lumen (arrow) can be seen alongside with
cells in the inner portions of the scaffold (arrowheads) (scale bar ¼ 300 mm). C, A transversal section of the scaffold
showing cells inside the PuraMatrix peptide solution inside the vessel lumen can be seen (*; scale bar ¼ 100 mm).
D, Another section showing cells lined in the lumen (arrow) and inside the inner collagenous portion of the scaffold
(arrowhead) (scale bar ¼ 100 mm).
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migrated inside the scaffold and reorganized into small
capillaries of three to four cells (Fig 5, B). Cells were also
positive for fascin antibody staining, which is a highly
expressed protein in endothelial cells33 (Fig 5, C).
The CM of cells cultivated with EIGF supplement pre-
sented statistically signiﬁcant higher concentrations ofsecreted vWF (P ¼ .0289) compared with the CM of cells
cultivated under regular culture medium (Fig 5, D). Fresh
culturemediumwith the same EIGF supplement concentra-
tion presented no detectable levels of vWF; therefore, all the
detectable vWF in the CM of the cultivated cells was
secreted by the cells. Normal human serum (positive reac-
tion control) presented 10 mg/mL of vWF.
Fig 4. Mesenchymal stem cells (MSCs) seeded in decellularized vein scaffolds, cultivated with endothelial inductor
growth factor (EIGF) supplementation, observed at phase-contrast inverted microscopy. A and B, Note the initial cells
adhering in the lumen of the decellularized scaffold (arrows) (scale bar ¼ 20 mm). C and D, After 1 week of cell
cultivation, the initial adhering cells seen at the previous ﬁgures presents a morphology shift, from rounded-shaped cells
to scamous/ﬂattened epithelial-shaped cells (arrowheads) (scale bar ¼ 40 mm).
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In this study, we evaluated the feasibility of a bioscaffold
obtained from decellularized veins, together with adipose-
derived MSCs, which were cultivated with EIGF supple-
mentation, aiming at the reconstruction of a functionally
active endothelium on the decellularized veins. Initially,
we demonstrated that when the MSCs were cultivated
during three passages, with constant culture medium
exchange, all the cells from the ﬁve different samples
(animal donors) presented morphologic features highly
characteristic of MSCs, and high expression of CD90,
considered as a MSC marker, in accordance to previous
reports.27,28 It is important to notice that these obtained
cells may have some degree of residual endothelial progen-
itor cells, which would contribute for the ﬁnal constructed
vessel. In this sense, future investigators should be aware of
this and if possible, employ further phenotypic proﬁling
using endothelial markers such as CD34, vascular endothe-
lial growth factor R2, and CD133.
After the characterization of the cell source, the next
step to obtain the desirable blood vessel substitute was
the seeding of these cells in a suitable 3D scaffold. Giventhat two-dimensional cell culture models does not allow
complex cell-to-ECM interactions35 and represent only
a fraction of the in vivo scenario, previous researchers
have reported that MSCs require a 3D structure to allow
ECM deposition and to successfully differentiate into
endothelial cells.36 In this sense, the following experiments
were performed to obtain the 3D scaffold capable of
housing the MSCs, thus giving them conditions to differ-
entiate into endothelial cells.
Three major characteristics are important for the
successful implementation of a scaffold in tissue engineering.
First, it needs to present a well-designed porous network37
(eg, the pore size and pore number needs to bewell balanced
given that higher porosity makes cell migration/prolifera-
tion more favorable). However, this same higher porosity
could also compromise the mechanical structure. Second,
it needs to degrade in a speed that is compatible to the
ECM production speed by the seeded cells so that the scaf-
fold material is gradually replaced by ECM proteins.38
Third, and easily understandable, it needs to be biocompat-
ible.28,37,38 Aiming to address all three required characteris-
tics, we proposed to employ decellularized vein fragments
Fig 5. Histologic sections of mesenchymal stem cell (MSC)-seeded vein fragments after the third week of endothelial
differentiation using endothelial inductor growth factor (EIGF) supplementation. A, Cells with evident endothelial
cell morphology lined on the lumen of the decellularized scaffolds (arrows) (low magniﬁcation; hematoxylin-eosin
staining; scale bar ¼ 20 mm). B, Transversal section showing a capillary-like structure (*) composed of three endothelial
cells (arrowheads) (hematoxylin-eosin staining; scale bar ¼ 20 mm). C, Anti-fascin monoclonal antibody staining of cells
lined in the scaffold’s lumen (arrows) (scale bar ¼ 10 mm). D, Quantiﬁcation of the von Willebrand factor (vWF) on
the conditioned medium (CM) of cells cultivated in the decellularized scaffolds, with regular cell culture medium and
EIGF supplemented medium. While the CM of cells cultivated under regular medium presents low levels of vWF, the
CM of cells cultivated with EIGF supplementation presents high detectable levels of this endothelial function marker.
Data are expressed as the mean6 standard deviation of seven individual enzyme-linked immunosorbent assay readings.
* Statistically signiﬁcant values with P < .05.
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(rejection component), displays a naturally occurring porous
network, possesses a nonimmunogenic 3D ECM structure,
and is a biocompatible structure. Moreover, this scaffold can
be considered bioactive, since it is accepted that the ECM
gives differentiation cues for the seeded cells.39,40
Therefore, we tested the SDS chemical decellularization
agent, which has proven to be efﬁcacious at removing the
immunogenic agents, in accordance with previous literature
reports.25 Interestingly, although it is alleged that SDS may
interfere with the ECM structure,41 it was only slightly
disorganized in our experiments, indicating that this effect
may be less deleterious at small tissue fragments, such as
blood vessels, which requires less exposure time to the agent.
Although only theMasson’s staining was performed, further
data in our laboratory support that SDS does not compro-
mise the ECM structure (data not published). In fact,
previous reports that SDS action on human great saphenous
veins did not compromise collagen morphology, induced
only a slight decrease in elastin staining, and left thebasement membrane unaffected41,42 further support our
ﬁndings. On the next experiments, when the characterized
MSCs were seeded on the scaffolds, the immunoﬂuores-
cence analysis revealed that the SDS treatment did not inter-
fere with the ability of cells to adhere to the scaffold, since
high cellularity was observed after only 60 minutes of cell
adhesion time. Moreover, some cells were seen at the inner
portions of the scaffold, indicating cell migration.
Having obtained the characterized cell source and the
decellularized scaffold, we then moved on to the ﬁnal
step of the study, which was to obtain a functional endo-
thelium. To accomplish this in the following experiments,
we employed the obtained decellularized scaffolds in
conjunction with characterized MSCs that were cultivated
on the scaffolds and in the presence of growth factors that
were obtained from platelets’ granules (EIGF). MSCs that
were cultivated on the scaffolds with basal medium only
were also investigated.
After 3 weeks of cell culture, the scaffolds were sub-
jected to histology, which revealed epithelial-like cells lined
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mous/ﬂattened cell morphology, but they were also stained
with a monoclonal antibody anti-fascin, which is considered
to be an endothelial differentiation marker.33,43 Intriguingly,
some sections revealed groups of three to four cells that
reorganized into capillary-like structures, with lumens, inside
the 3D scaffolds. To further characterize these cells as endo-
thelial cells, we quantiﬁed the vWF protein concentration at
the CM of cells cultivated with and without EIGF supple-
mentation. These ﬁnal analyses revealed that when the cells
are cultivated on the scaffold with basal medium, low levels
of vWF are detectable, indicating that some differentiation
cues are due to the retained ECM proteins on the decellu-
larized scaffolds, as described elsewhere.39,40 However,
when EIGF supplementation is added to the cell cultures,
statistically signiﬁcant high levels of vWF are obtained, indi-
cating that the combination of the bioscaffold and EIGF are
important to the endothelial cell differentiation. Moreover,
these high levels of vWF further support the ﬁndings on
the histology and general morphology analyses.
Although there are a number of published reports and
interesting ﬁndings in the ﬁeld of blood vessel tissue engi-
neering, most of them employ synthetic scaffolds for the
cells with puriﬁed recombinant growth factors. For
a detailed review on these ﬁndings, readers should seek
the paper by Nemeno-Guanzon et al.36 Only a few authors
have investigated the use of decellularized bioscaffolds for
blood vessel engineering.38
In this sense, future studies should explore the present
reported ﬁndings, possibly expanding it with the addition
of smooth muscle cells given its crucial role in the homeo-
stasis on blood vessels physiology.36
CONCLUSIONS
This report demonstrates that adipose-derived MSCs
cultivated at a decellularized vein scaffold differentiated into
functional endothelial cells. These secreted vWF on the
culture medium through the induction of growth factors ob-
tained from platelets. Moreover, the decellularized bio-
scaffolds promoted cell adhesion, suggesting that it can be
employed as a cell-housing facility. Taken together, bio-
scaffold, cell source, and the method of differentiation seem
to be an interesting approach to obtain bioengineered blood
vessel substitutes. These, then, could be upgraded with
smooth muscle cells and further explored within in vivo
experiments as vein grafts in future investigations.
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